The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Generic Colchicine Approved for Gout Prophylaxis

Generic Colchicine Approved for Gout Prophylaxis

March 1, 2015 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with acute gout and other inflammatory diseases may soon have access to less expensive colchicine therapy, thanks to a federal judge and a years-long effort by the ACR. But the fight’s not done yet.

You Might Also Like
  • FDA Enforcement Against Injectable Colchicine
  • U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Explore This Issue
March 2015
Also By This Author
  • Professional Athlete’s Arthritis Diagnosis a Wake-Up Call for Physicians

A Jan. 9 ruling from the U.S. Court of Appeals in Delaware immediately allowed West-Ward Pharmaceutical Corp. and Hikma Pharmaceuticals Inc. to offer generic colchicine products to the market for prophylactic gout treatment. Although an appeal from the current producer, Takeda, is in progress, the ACR pledges to continue keeping a wary eye on patient and physician access to much-needed medications at more affordable prices.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background

The current case began after West-Ward and Hikma received FDA approval in September 2014 for Mitigare, a 0.6 mg colchicine capsule for prophylactic gout treatment. Takeda Pharmaceuticals USA Inc. then filed a patent infringement suit to block Mitigare from the market. URL Pharma of Philadelphia, which was later sold to Takeda, received FDA approval for its colchicine drug, Colcrys, in 2009, along with the exclusive right to market colchicine for acute gout flares (https://www.the-rheumatologist.org/details/article/865591/Colcrys_Approval_Triggers_Questions.html). Other companies that had previously been producing colchicine for this application—Hikma among them—were ordered to stop marketing their versions of colchicine.

Since then, the price of colchicine has risen from $0.09/dose to $5/dose, a 50-fold jump.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Generic Colchicine Approved for Gout Prophylaxis

The ACR has been battling against Colcrys as the sole treatment option since the FDA granted its approval six years ago. Before then, colchicine was already being used and was widely viewed as safe and effective. In fact, it was among the most routine treatment options for patients with gout. But URL Pharma took advantage of an FDA program to formalize approval for previously unapproved medications and became the first official purveyor of colchicine. That granted the company a three-year window of exclusivity, and the price spike followed.

URL Pharma “basically found a loophole in the system,” says former ACR President Stanley Cohen, MD, co-director of the Division of Rheumatology at Presbyterian Hospital in Dallas. “They were able to charge outrageous prices for a drug that didn’t require outrageous prices.”

The Current Battle

Takeda, which acquired URL Pharma in 2012, has fought to protect that exclusivity. In September, Hikma was granted approval to market and sell a version of colchicine, but Takeda obtained a temporary restraining order.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR filed an amicus curiae brief in the case, arguing that preventing Mitigare from reaching the market was a disservice to patients.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Crystal Arthritis, DMARDs & Immunosuppressives, Drug Updates, Legislation & Advocacy Tagged With: Colchicine, Gout, Quinn, Research, rheumatology, TreatmentIssue: March 2015

You Might Also Like:
  • FDA Enforcement Against Injectable Colchicine
  • U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)